# Wet Tap-Induced Spinal Cord Stimulator Trial Failure in Failed Back Surgery Syndrome: A Case Report Highlighting Intrathecal Drug Delivery for Treatment-Resistant Pain

## TL;DR

A patient with chronic back pain failed a spinal cord stimulator trial due to complications and found success with an intrathecal drug delivery system.

## Contribution

Demonstrates intrathecal drug delivery as an effective alternative when spinal cord stimulator trials fail due to procedural complications.

## Key findings

- Spinal cord stimulator trial failed due to dural puncture and CSF leakage.
- Intrathecal pump trial provided 90% pain relief and led to permanent implantation.
- Procedural complications can significantly impact neuromodulation outcomes.

## Abstract

A 59-year-old female with failed back surgery syndrome (FBSS) following multiple lumbar surgeries underwent a spinal cord stimulator (SCS) trial for chronic pain management. However, the trial failed due to severe nausea, vomiting, and postural headaches secondary to unintentional dural puncture (wet tap) during lead placement. This resulted in cerebrospinal fluid (CSF) leakage, low-pressure headaches, and subsequent trial intolerance, necessitating early lead removal. Given her failed response to conservative treatments, neuropathic medications, and systemic opioids, an intrathecal pump (ITP) trial was pursued, yielding 90% pain relief and leading to permanent pump implantation. This case highlights the impact of procedural complications on neuromodulation outcomes and the role of intrathecal drug delivery as an alternative in patients who cannot tolerate SCS.